Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.

This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.

In this study, the researchers developed a cellulose nanofiber-based scaffold containing sitagliptin and zinc sulfide nanoparticles, which promoted scarless healing and hair follicle regeneration in rats by targeting DPP4+ fibroblasts, suggesting a novel approach for improved wound healing and skin regeneration.

In this study, researchers found that topical application of the diabetes medication Sitagliptin in mice accelerates hair follicle regeneration and reduces fibrosis, suggesting it could be repurposed to treat hair loss conditions like alopecia.

This study found that DPP4 inhibition in mice can enhance hair follicle activation and regeneration, suggesting a potential therapeutic strategy for improving hair growth and wound-induced hair follicle neogenesis.